Ticker HubNasdaq
NTLA
Intellia Therapeutics, Inc
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Latest price
$0.0000+0.00%
As of — · Market data by Massive
Market cap
$1.4B
Volume
0
Previous close
$9.70
Day range
$0.0000 – $0.0000
Listed
May 6, 2016
Coverage
2 articles
Price performance
Recent trading
Five-day open $12.01Latest interval $9.75
Newsroom
Latest NTLA coverage

CompanyDeep DiveNov 20, 2025
Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?
Intellia plunged after a patient died in its ATTR trial, prompting FDA holds on two Phase III studies and raising serious questions about safety, CRISPR risks, and the future of its pipeline.
NTLA
SCD
NewsNov 6, 2022
Novel gene-editing therapy shows promise for patients with transthyretin amyloid cardiomyopathy
[ad_1] Research Highlights: In a clinical trial, a single intravenous infusion of NTLA-2001, a novel gene-editing therapy based on CRISPR/Cas9, significantly reduced abnormal levels of the protein transthyretin in patients with ATTR amyloid cardiomyopathy, a progressive and fatal cause of heart failure. Circulating TTR protein, which accumulates in the
NTLAATTRTTRCT
Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.